Literature DB >> 23647091

The natural history of actinic keratosis: a systematic review.

R N Werner1, A Sammain, R Erdmann, V Hartmann, E Stockfleth, A Nast.   

Abstract

Knowledge about the development of untreated actinic keratosis (AK) and risk of progression into squamous cell carcinoma (SCC) is important. Therefore, we set out to synthesize primary data on the natural history of AK. We carried out a systematic literature search (Medline, Medline in Process, Embase, Cochrane) of studies on the natural course of AK, regarding (i) progression and regression rates per lesion-year, (ii) changes in total lesion counts over time, and (iii) spontaneous field regression and recurrence rates, taking into account studies on participants without immunosuppression and history of skin cancer, immunosuppressed patients and participants with a history of skin cancer and sunscreen use. Twenty-four eligible studies were identified providing data on at least one of the outcomes. Progression rates of AK to SCC ranged from 0% to 0·075% per lesion-year, with a risk of up to 0·53% per lesion in patients with prior history of nonmelanoma skin cancer. Rates of regression of single lesions ranged between 15% and 63% after 1 year. The data available on recurrence rates of single lesions 1 year after regression indicate a recurrence rate of 15-53%. Data on the relative change of total AK count over time are heterogeneous, and range from -53% to +99·1%. Spontaneous complete field regression rates range from 0% to 21%, with recurrences in 57%. In general, the available data are limited. Important methodological limitations apply. Currently, no reliable estimates concerning the frequency of AK developing into invasive carcinoma can be given, and further studies are needed.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2013        PMID: 23647091     DOI: 10.1111/bjd.12420

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  64 in total

Review 1.  [Actinic keratosis, Bowen's disease, keratoacanthoma and squamous cell carcinoma of the skin].

Authors:  M Majores; E Bierhoff
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

2.  Comparison of "Lesion-by-Lesion" and Field Photodynamic Therapy in the Prevention of Actinic Keratoses: A Randomized, Split-Face, Single-Blind Pilot Study.

Authors:  Inge Seubring; Joannes M M Groenewoud; Marie-Jeanne P Gerritsen
Journal:  Dermatology       Date:  2017-01-18       Impact factor: 5.366

3.  Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.

Authors:  Abby R Rosenberg; Mary Tabacchi; Kenneth H Ngo; Michael Wallendorf; Ilana S Rosman; Lynn A Cornelius; Shadmehr Demehri
Journal:  JCI Insight       Date:  2019-03-21

Review 4.  [Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options].

Authors:  T Strunk; R-M Szeimies
Journal:  Hautarzt       Date:  2014-03       Impact factor: 0.751

5.  Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.

Authors:  James Q Del Rosso; Leon Kircik; Gary Goldenberg; Berman Brian
Journal:  J Clin Aesthet Dermatol       Date:  2014-09

6.  The clinical course of actinic keratosis correlates with underlying molecular mechanisms.

Authors:  A Bakshi; R Shafi; J Nelson; W C Cantrell; S Subhadarshani; A Andea; M Athar; C A Elmets
Journal:  Br J Dermatol       Date:  2019-09-11       Impact factor: 9.302

Review 7.  [Current guidelines in dermatology : A selection of clinically relevant recommendations].

Authors:  A Nast; S Rosumeck; R Erdmann; C Dressler; R N Werner
Journal:  Hautarzt       Date:  2016-05       Impact factor: 0.751

Review 8.  [The aged scalp : A dermato-oncological focus point].

Authors:  N Wroblewski; K Wylon; C Ulrich
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

9.  Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial.

Authors:  Brian Berman; Stephen Tyring; Walter K Nahm; Marie Louise Østerdal; Astrid H Petersen; Daniel M Siegel
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

10.  Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL).

Authors:  Kelly Vis; Rick Waalboer-Spuij; Dyon G C T M Snels; Loes M Hollestein
Journal:  Dermatology       Date:  2018-06-15       Impact factor: 5.366

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.